Potent antitumor activities of recombinant human PDCD5 protein in combination with chemotherapy drugs in K562 cells

Journal Article · Fri May 28 00:00:00 EDT 2010 · Biochemical and Biophysical Research Communications

DOI:https://doi.org/10.1016/J.BBRC.2010.04.068· OSTI ID:22202608

Shi, Lin ^[1]; Song, Quansheng; Zhang, Yingmei ^[2]; Lou, Yaxin ^[3]; Wang, Yanfang ^[1]; Tian, Linjie; Zheng, Yi; Ma, Dalong ^[2]; Ke, Xiaoyan ^[1]; Wang, Ying ^[2]

---

1. Department of Hematology, The Third Hospital, Peking University, 49 Huayuan North Road, Beijing 100191 (China)
2. Peking University Center for Human Disease Genomics, 38 Xueyuan Road, Beijing 100191 (China)
3. Peking University Medical and Health Analysis Center, Peking University Health Science Center, 38 Xueyuan Road, Beijing 100191 (China)

Conventional chemotherapy is still frequently used. Programmed cell death 5 (PDCD5) enhances apoptosis of various tumor cells triggered by certain stimuli and is lowly expressed in leukemic cells from chronic myelogenous leukemia patients. Here, we describe for the first time that recombinant human PDCD5 protein (rhPDCD5) in combination with chemotherapy drugs has potent antitumor effects on chronic myelogenous leukemia K562 cells in vitro and in vivo. The antitumor efficacy of rhPDCD5 protein with chemotherapy drugs, idarubicin (IDR) or cytarabine (Ara-C), was examined in K562 cells in vitro and K562 xenograft tumor models in vivo. rhPDCD5 protein markedly increased the apoptosis rates and decreased the colony-forming capability of K562 cells after the combined treatment with IDR or Ara-C. rhPDCD5 protein by intraperitoneal administration dramatically improved the antitumor effects of IDR treatment in the K562 xenograft model. The tumor sizes and cell proliferation were significantly decreased; and TUNEL positive cells were significantly increased in the combined group with rhPDCD5 protein and IDR treatment compared with single IDR treatment groups. rhPDCD5 protein, in combination with IDR, has potent antitumor effects on chronic myelogenous leukemia K562 cells and may be a novel and promising agent for the treatment of chronic myelogenous leukemia.

• OSTI ID: 22202608
• Journal Information: Biochemical and Biophysical Research Communications, Vol. 396, Issue 2; Other Information: Copyright (c) 2010 Elsevier Science B.V., Amsterdam, The Netherlands, All rights reserved.; Country of input: International Atomic Energy Agency (IAEA); ISSN 0006-291X
• Country of Publication: United States
• Language: English

Related Subjects

60 APPLIED LIFE SCIENCES
APOPTOSIS
CELL PROLIFERATION
CHEMOTHERAPY
DRUGS
IN VITRO
IN VIVO
LEUKEMIA
PATIENTS
PROTEINS
TUMOR CELLS